Intratumoral Cancer Therapies Market Outlook 2034: Growth Trends, Competitive Landscape, and Future Opportunities - DelveInsight

The Intratumoral Cancer Therapies market is expected to grow at a CAGR of 49.10% during the forecast period (2025-2034), driven by the launch of emerging oncolytic viruses, immunostimulants, and other locally delivered agents, along with the need for options that reduce systemic toxicity. A growing pipeline across melanoma, lung, pancreatic, prostate, and skin cancers is expected to reshape the localized oncology treatment landscape.
DelveInsight's "Intra-Tumoral Cancer Therapies Treatment Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of intratumoral cancer therapies, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the Intratumoral Cancer Therapies market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here; Intratumoral Cancer Therapies Market Forecast - https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Some of the key facts of the Intratumoral Cancer Therapies Market Report:
• The Intratumoral Cancer Therapies market size across the 7MM was valued at approximately USD 115 million in 2025 and is projected to reach USD 4,193 million by 2034, at a CAGR of 49.10%.
• Only three intratumoral cancer therapies are currently approved: IMLYGIC (talimogene laherparepvec; Amgen), approved in the US and Europe in 2015; HENSIFY (NBTXR3; Nanobiotix/Janssen), approved in Europe in 2019 for soft tissue sarcoma; and DELYTACT (teserpaturev; Daiichi Sankyo), conditionally approved in Japan in 2021 for malignant glioma.
• The US FDA accepted the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec; Replimune) in combination with nivolumab for advanced melanoma.
• In March 2025, Nanobiotix announced topline data from the completed dose-escalation portion of a Phase I study, sponsored by MD Anderson Cancer Center, of NBTXR3 (JNJ-1900) activated by radiation therapy in locally advanced NSCLC patients eligible for re-irradiation.
• In January 2025, Stamford Pharmaceuticals announced positive Phase IIa results for SP-002 in combination with vismodegib in patients with multiple basal cell carcinoma (BCC).
• In January 2025, Lokon Pharma announced that the FDA granted Fast Track Designation to LOAd703 for pancreatic cancer.
• Cytovation ASA anticipated starting Phase II of CY-101 as monotherapy in adrenocortical carcinoma (ACC) in the first half of 2025, and Phase I/II in combination with KEYTRUDA in colorectal cancer in the second half of 2025.
• By 2034, CAN-2409 (Candel Therapeutics), under development for prostate cancer, NSCLC, and pancreatic cancer, is expected to achieve the highest market size across the US, EU4, the UK, and Japan.
• The US accounts for the largest intratumoral cancer therapies market size, owing to the highest number of eligible cases, higher treatment costs, and the launch of emerging drugs, followed by Germany and Italy by 2034.
• As per DelveInsight analysis, the total indication-wise eligible cases were approximately 1.94 million in the 7MM in 2024, and these are anticipated to increase by 2034.
• In the 7MM in 2024, BCC accounted for the highest number of diagnosed prevalent cases among the indications studied, while ACC accounted for the lowest.
• Intratumoral therapies deliver antitumor agents directly into tumors to induce local tumor death, release antigens, and activate a localized immune response, with the potential for systemic (abscopal) effects. They also reduce systemic toxicity while achieving high drug levels at the tumor site.
• Key Intratumoral Cancer Therapies Companies: Amgen, Daiichi Sankyo, Nanobiotix/Janssen Pharmaceutical, Replimune, Candel Therapeutics, Intensity Therapeutics, Philogen S.p.A., QBiotics, Highlight Therapeutics, Lytix Biopharma, Medicenna Therapeutics, Cytovation, Lokon Pharma, Stamford Pharmaceuticals, and others
• Key Intratumoral Cancer Therapies: IMLYGIC, DELYTACT, HENSIFY (NBTXR3), RP1 (vusolimogene oderparepvec), Nidlegy (Daromun), INT230-6, BO-112, Bizaxofusp (MDNA55), Tigilanol tiglate, CAN-2409, and others

Intratumoral Cancer Therapies Overview
Intratumoral cancer therapies refer to any therapy delivered in very close anatomical proximity to a tumor with the intention of direct uptake by tumors or tumor cells. Approaches under clinical development include radioenhancer nanoparticles, recombinant fusion proteins, oncolytic viruses, gene therapy, synthetic dsRNA complexes, and others. Delivering immunostimulatory products directly into a primary or metastatic lesion aims to prime and boost an antitumor immune response.
Many tumors are immunosuppressive. Regulatory T cells and anti-inflammatory cytokines such as TGF-β and IL-10 suppress antigen-presenting cells and let malignant cells escape immune detection. Intratumoral immunostimulants can overcome this suppressive environment by recruiting immune cells and activating T cells that recognize tumor antigens. Those T cells can then circulate back to the injected tumor or to distal tumors.
Established options such as immunotherapy, radiotherapy, chemotherapy, and targeted therapy have improved outcomes but cannot benefit every patient. Some cannot reach targets deep within tumor tissue, and some cause serious adverse events. Intratumoral delivery offers a local approach that may suit patients who are unsuitable for systemic treatments.

Get a Free sample for the Intratumoral Cancer Therapies Market Report: https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Intratumoral Cancer Therapies Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major markets (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders, and includes a detailed analysis of the patient pool and future trends.

Intratumoral Cancer Therapies Epidemiology Segmentation:
The Intratumoral Cancer Therapies market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Cases of Selected Indications in the 7MM
• Indication-wise Target Patient Pool of Intratumoral Cancer Therapies in the 7MM
• Indication-wise Treated Cases of Intratumoral Cancer Therapies in the 7MM

Download the report to understand which factors are driving Intratumoral Cancer Therapies epidemiology trends @ Intratumoral Cancer Therapies Epidemiology Forecast - https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Intratumoral Cancer Therapies Market
The dynamics of the Intratumoral Cancer Therapies market are anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecast period 2025-2034. Philogen and Replimune have late-stage programs, while companies including Highlight Therapeutics, Cytovation, Intensity Therapeutics, Treovir, QBiotics, NanOlogy, EpicentRx, and Medicenna Therapeutics have candidates in Phase II. Uptake will depend on the competitive landscape, safety and efficacy data, and order of entry.
"Intra-tumoral (intralesional) immunotherapeutic delivery is a compelling solution to address local impediments to tumor immunity."

Intratumoral Cancer Therapies and Key Companies
• IMLYGIC (talimogene laherparepvec): Amgen
• DELYTACT (teserpaturev/G47Δ): Daiichi Sankyo
• HENSIFY (NBTXR3): Nanobiotix/Janssen Pharmaceutical
• RP1 (vusolimogene oderparepvec): Replimune
• Nidlegy (Daromun): Philogen S.p.A.
• INT230-6: Intensity Therapeutics
• BO-112: Highlight Therapeutics
• Bizaxofusp (MDNA55): Medicenna Therapeutics
• Tigilanol tiglate: QBiotics
• CAN-2409: Candel Therapeutics
• LOAd703: Lokon Pharma
• CY-101: Cytovation

To know more about Intratumoral Cancer Therapies treatment, visit @ Intratumoral Cancer Therapies Medications-https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Intratumoral Cancer Therapies Market Drivers
• Growing Strategic Focus on Localized Oncology Treatments
• Reduced Systemic Toxicity with High Drug Levels at the Tumor Site
• Potential Systemic (Abscopal) Immune Effects
• Limitations of Existing Systemic Cancer Therapies
• Robust Pipeline of Oncolytic Viruses, Immunostimulants, and Nanoparticle Therapies
• Expected Launch of Emerging Therapies

Intratumoral Cancer Therapies Market Barriers
• Very Few Approved Therapies
• Higher Treatment Costs
• Need for Careful Comparator Selection in Pivotal and Confirmatory Trials
• Development Programs Being Reprioritized (e.g., Ilixadencel)
• Reimbursement and Market Access Challenges

Scope of the Intratumoral Cancer Therapies Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM
• Key Intratumoral Cancer Therapies Companies: Amgen, Daiichi Sankyo, Nanobiotix/Janssen Pharmaceutical, Intensity Therapeutics, Philogen S.p.A., Replimune, QBiotics, and others
• Key Intratumoral Cancer Therapies: INT230-6, Vusolimogene oderparepvec (RP1), Nidlegy (Daromun), BO-112, Bizaxofusp (MDNA55), and others
• Intratumoral Cancer Therapies Therapeutic Assessment: Intratumoral Cancer Therapies current marketed and Intratumoral Cancer Therapies emerging therapies
• Intratumoral Cancer Therapies Market Dynamics: Intratumoral Cancer Therapies market drivers and Intratumoral Cancer Therapies market barriers
• Competitive Intelligence Analysis: SWOT analysis and Analyst Views
• Intratumoral Cancer Therapies Unmet Needs, KOL's views, Analyst's views, Intratumoral Cancer Therapies Market Access and Reimbursement

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.